| abstract |
There is provided a pharmaceutical formulation that can be used topically comprising a leukotriene receptor antagonist, a salt or a solvate thereof. Specific leukotriene receptor antagonists that may be mentioned include montelukast styrene. The formulations are particularly useful for direct topical administration for the treatment of inflammation, inflammatory disorders and/or conditions characterized by inflammation including wounds, burns, psoriasis, hemorrhoids, acne and atopic dermatitis. |